{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T03:26:29Z","timestamp":1762917989535,"version":"3.37.3"},"reference-count":14,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2019,4,23]],"date-time":"2019-04-23T00:00:00Z","timestamp":1555977600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"DOI":"10.1371\/journal.pmed.1002791","type":"journal-article","created":{"date-parts":[[2019,4,23]],"date-time":"2019-04-23T17:25:08Z","timestamp":1556040308000},"page":"e1002791","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":9,"title":["Tuberculosis vaccines: Rising opportunities"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3325-9073","authenticated-orcid":true,"given":"Johan","family":"Vekemans","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine L.","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy","family":"Farrar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2019,4,23]]},"reference":[{"key":"ref1","unstructured":"W9WHO. Global Tuberculosis Report 2018. Available from: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.who.int\/tb\/publications\/global_report\/en\/\" xlink:type=\"simple\">https:\/\/www.who.int\/tb\/publications\/global_report\/en\/<\/ext-link>. [cited 2019 Mar 4]."},{"key":"ref2","unstructured":"WHO Global Tuberculosis Program communication about the adoption by the UN General Assembly of the Declaration from the first-ever United Nations High Level Meeting on TB. Available from: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.who.int\/tb\/features_archive\/UNGA-adopts-TB-declaration\/en\/\" xlink:type=\"simple\">https:\/\/www.who.int\/tb\/features_archive\/UNGA-adopts-TB-declaration\/en\/<\/ext-link>. [cited 2019 Mar 4]."},{"issue":"11","key":"ref3","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1080\/21645515.2016.1205769","article-title":"Systematic review of mathematical models exploring the epidemiological impact of future TB vaccines","volume":"12","author":"RC Harris","year":"2016","journal-title":"Hum Vaccin Immunother"},{"issue":"17","key":"ref4","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1803484","article-title":"Phase 2b Controlled Trial of M72\/AS01E Vaccine to Prevent Tuberculosis","volume":"379","author":"O Van Der Meeren","year":"2018","journal-title":"N Engl J Med"},{"issue":"8","key":"ref5","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S1473-3099(18)30421-3","article-title":"WHO preferred product characteristics for new vaccines against tuberculosis","volume":"18","author":"LK Schrager","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"ref6","doi-asserted-by":"crossref","first-page":"e209","DOI":"10.1016\/S2214-109X(18)30452-2","article-title":"Age-targeted tuberculosis vaccination in China and implications for vaccine development: a modelling study","volume":"7","author":"RC Harris","year":"2019","journal-title":"Lancet Glob Health"},{"issue":"2","key":"ref7","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1714021","article-title":"Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination","volume":"379","author":"E Nemes","year":"2018","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0140-6736(96)02166-6","article-title":"Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi","volume":"348","year":"1996","journal-title":"Lancet"},{"issue":"9493","key":"ref9","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/S0140-6736(05)67145-0","article-title":"Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial","volume":"366","author":"LC Rodrigues","year":"2005","journal-title":"Lancet"},{"key":"ref10","unstructured":"Evidence review for SAGE recommendation on BCG revaccination. Available from: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.who.int\/immunization\/policy\/position_papers\/bcg_evidence_recommendation_table_revaccination.pdf?ua=1\" xlink:type=\"simple\">https:\/\/www.who.int\/immunization\/policy\/position_papers\/bcg_evidence_recommendation_table_revaccination.pdf?ua=1<\/ext-link>. [cited 2019 Mar 4]."},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.12688\/f1000research.16521.1","article-title":"Research and development of new tuberculosis vaccines: a review","volume":"7","author":"LK Schrager","year":"2018","journal-title":"F1000Res"},{"key":"ref12","unstructured":"Global report on tuberculosis vaccines 2018. Available from: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.tbvi.eu\/wp-content\/uploads\/2018\/02\/Summary-SWRTV_Finalproof.pdf\" xlink:type=\"simple\">https:\/\/www.tbvi.eu\/wp-content\/uploads\/2018\/02\/Summary-SWRTV_Finalproof.pdf<\/ext-link>. [cited 2019 Mar 4]."},{"key":"ref13","unstructured":"G-finder 2018. Policy cures research. Neglected disease research and development: reaching new heights. 2018. Available from: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.policycuresresearch.org\/wp-content\/uploads\/Y11_G-FINDER_Full_report_Reaching_new_heights.pdf\" xlink:type=\"simple\">https:\/\/www.policycuresresearch.org\/wp-content\/uploads\/Y11_G-FINDER_Full_report_Reaching_new_heights.pdf<\/ext-link>. [cited 2019 Mar 4]."},{"key":"ref14","unstructured":"TB Vaccine Research and Development: A Business Case for Investment. 2013. Available from: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.gov.uk\/dfid-research-outputs\/tb-vaccine-research-and-development-a-business-case-for-investment\" xlink:type=\"simple\">https:\/\/www.gov.uk\/dfid-research-outputs\/tb-vaccine-research-and-development-a-business-case-for-investment<\/ext-link>. [cited 2019 Mar 4]."}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pmed.1002791","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T06:41:35Z","timestamp":1589006495000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1002791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,23]]},"references-count":14,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,4,23]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1002791","relation":{},"ISSN":["1549-1676"],"issn-type":[{"type":"electronic","value":"1549-1676"}],"subject":[],"published":{"date-parts":[[2019,4,23]]}}}